A study highlighted in the journal Hypertension indicates promising benefits of tirzepatide, a novel weight loss medication, in reducing systolic blood pressure among obese adults. Over eight months, the research involved nearly 500 participants who showed significant decreases in systolic blood pressure while using tirzepatide. This medication operates by mimicking glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, thereby enhancing insulin secretion and sensitivity post-meal, which aids in regulating blood sugar levels, slowing digestion, and curbing appetite—ultimately leading to weight loss.
Systolic blood pressure, the higher number in a blood pressure reading, holds more excellent predictive value for cardiovascular mortality than diastolic pressure. According to the American Heart Association’s 2024 statistics, 47% of adults in the United States are afflicted with hypertension, with nearly 42% classified as obese. These statistics underscore the critical need for effective treatments that concurrently address both conditions.
Tirzepatide gained initial approval from the FDA in 2022 for managing Type 2 diabetes and subsequently received approval in late 2023 for chronic weight management in adults with obesity or overweight who have related health conditions like hypertension and diabetes. This dual approval highlights its potential to mitigate multiple health risks associated with obesity, including high blood pressure.
Lead author Dr James A. de Lemos, from UT Southwestern Medical Center, Dallas, noted the study’s findings suggest that tirzepatide not only aids in weight loss but also shows impressive reductions in blood pressure among participants. The study, a planned sub-study within the larger SURMOUNT-1 trial, focused on assessing tirzepatide’s impact on blood pressure using 24-hour ambulatory monitoring in individuals with obesity but without Type 2 diabetes.
Participants in the sub-study were randomly assigned to receive either tirzepatide at varying doses (5 mg, 10 mg, or 15 mg) or a placebo. The results after 36 weeks revealed dose-dependent reductions in systolic blood pressure: 7.4 mm Hg for the 5 mg dose, 10.6 mm Hg for the 10 mg dose, and 8.0 mm Hg for the 15 mg dose. These reductions were consistent across participant subgroups categorized by age, sex, BMI, and hypertension-related risk factors.
Ambulatory blood pressure monitoring, which provides more comprehensive data than traditional office measurements, was used throughout the study. This method involved continuous monitoring over 24 to 27 hours, capturing daytime and nighttime readings. The study’s rigour ensured robust data analysis, though limitations included its subset nature and the limited frequency of nighttime readings.
Dr Michael E. Hall, commenting on the broader implications, highlighted the potential of tirzepatide and similar medications in not only addressing obesity-related complications but also potentially reducing cardiovascular risks associated with conditions like hypertension and diabetes. However, he emphasized the need for further research to ascertain long-term cardiovascular outcomes and the effects on blood pressure post-medication cessation.
In conclusion, the study underscores tirzepatide’s dual benefits in weight management and blood pressure reduction among obese individuals. Future investigations will be crucial in elucidating its sustained effects and broader implications for cardiovascular health, offering hope for improved management strategies against rising global obesity-related health challenges.
More information: James A. de Lemos et al, Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy, Hypertension. DOI: 10.1161/HYPERTENSIONAHA.123.22022
Journal information: Hypertension Provided by American Heart Association
